Inovio Pharma (Nasdaq: INO) announced its newest DNA-based cancer immunotherapy targeting melanoma induced a robust and broad immune response in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE